Assessing compliance of cardiologists with the national cholesterol education program (NCEP) III guidelines in an ambulatory care setting

Lipids in Health and Disease

Volumn 3, Issue , 2004, Pages

  Aliyu, Zakari Y ^a,b   Yousif, Souhair B ^a   Plantholt, Kate ^a   Salihu, Hamisu ^c   Erinle, Ayodele ^a   Plantholt, Steve ^a  

^a ST AGNES HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOLOGY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 2942532693     PISSN: 1476511X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-511X-3-9     Document Type: Article

References (18)

1. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994; 16:366-385.
2. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989; 80:1313-1319.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009
5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389
6. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991; 151:43-49.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.
8. Davidson MH. Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 7;89(5A):8C-20C
9. Eaton CB, Stamp MJ; National Cholesterol Education Program 9NCEP) - The Adult Treatment Panel III Guidelines. Practice patterns related to the Adult Treatment Panel III guidelines in primary care. Am J Cardiol. 2002 Sep 15;90(6):687
10. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002 Jan 15;105(2):152-6
11. Hoekstra JW, Pollack CV, Roe MT. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med. 2002 Nov;9(11):1146-55
12. De Bacquer G: Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl. 2002 Apr;2(4):13-6; discussion 16-7. Review
13. De Bacquer D, De Backer G, Ostor E, Simon J, Prorala K; EUROASPIRE 1 Study Group: Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil. 2003 Aug;10(4):289-95
14. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol. 1998; 82:311-316.
15. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol. 1998; 82:40J-46J.
16. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Kara RH. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 2003 Oct 21;139(8):670-82
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 08
18. Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med. 2004 Apr 8;350(15):1562-4. Epub 2004 Mar